Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Vij

Showing results (101-110 of 283) with videos related to

Pageof 29
Sort By:
Blood|April 23, 2008
Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interactionSteven M Devine, Ravi Vij, Michael Rettig, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 15, 2017
T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid LeukemiaJoan How, Michael Slade, Khoan Vu, et al.
British Journal of Haematology|April 3, 2019
Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013Vincent Ribrag, David E Avigan, Damian J Green, et al.
Transplantation and Cellular Therapy|November 11, 2025
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate E-Selectin Inhibition with Uproleselan to Reduce Gastrointestinal Toxicity During Autologous Hematopoietic Cell Transplantation for Multiple MyelomaZachary D Crees, Keith Stockerl-Goldstein, Meaghan Ryan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 25, 2007
A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantationThomas Fong, Kathryn Trinkaus, Douglas Adkins, et al.
Haematologica|April 16, 2016
Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stromaPilar de la Puente, Nancy Quan, Ryan Soo Hoo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2019
A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple MyelomaMark A Schroeder, Mark A Fiala, Eric Huselton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myelomaSagar Lonial, Ravi Vij, Jean-Luc Harousseau, et al.
Blood|October 31, 2002
Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantationRavi Vij, John F DiPersio, Partha Venkatraman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2006
Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamideChristopher L Hallemeier, Mark D Girgis, William G Blum, et al.
Pageof 29

Showing results (101-110 of 283) with videos related to

Sort By:
Pageof 29
Blood|April 23, 2008
Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interactionSteven M Devine, Ravi Vij, Michael Rettig, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 15, 2017
T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid LeukemiaJoan How, Michael Slade, Khoan Vu, et al.
British Journal of Haematology|April 3, 2019
Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013Vincent Ribrag, David E Avigan, Damian J Green, et al.
Transplantation and Cellular Therapy|November 11, 2025
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate E-Selectin Inhibition with Uproleselan to Reduce Gastrointestinal Toxicity During Autologous Hematopoietic Cell Transplantation for Multiple MyelomaZachary D Crees, Keith Stockerl-Goldstein, Meaghan Ryan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 25, 2007
A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantationThomas Fong, Kathryn Trinkaus, Douglas Adkins, et al.
Haematologica|April 16, 2016
Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stromaPilar de la Puente, Nancy Quan, Ryan Soo Hoo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2019
A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple MyelomaMark A Schroeder, Mark A Fiala, Eric Huselton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myelomaSagar Lonial, Ravi Vij, Jean-Luc Harousseau, et al.
Blood|October 31, 2002
Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantationRavi Vij, John F DiPersio, Partha Venkatraman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2006
Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamideChristopher L Hallemeier, Mark D Girgis, William G Blum, et al.
Pageof 29